Mycofenolatmofetil Actavis (mycophenolate mofetil) is the generic equivalent of Roche’s Cellcept, and is used with other medicines to lower the body’s immunity after heart, kidney or liver transplant.
The original contract between Nordion (formerly MDS) and Capgemini was effective June 2006, and this current contract extension calls for Capgemini to continue to provide information technology (IT)
Additionally, combined data from three other Phase III studies showed that RA patients who received Actemra had sustained improvements in signs and symptoms over nearly two years. Across
Lodotra is a proprietary programmed-release formulation of low-dose prednisone and has received regulatory approval in Europe for reduction in morning stiffness associated with rheumatoid arthritis (RA). Merck Serono
Kombiglyze XR is a once-a-day metformin extended-release (XR) plus dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet offering glycaemic control across glycosylated haemoglobin levels (HbA1c), fasting plasma glucose (FPG) and
Headquartered in Pleasanton, CA, IntegenX is a privately held company that designs, manufactures and markets automated DNA- and RNA-based sample preparation systems for life sciences, applied sciences and
Genesis Biopharma is developing its anti-CD55 antibody therapy to neutralize a key cancer defense mechanism that has been found to be over-expressed in more than 80% of solid
The agreement grants Nutrition 21 an exclusive license in the US and Canada for Coldizin, an ingredient combination, patented in the US and Europe, for enhancing upper-respiratory health.
Targacept has posted a net income of $2.49m for the third quarter 2010, or $0.08 per diluted share, compared to $1.33m, or $0.05 per diluted share, for the
Senesco president and CEO Leslie Browne said that they are pleased to receive this grant to support continued development of SNS01-T, company’s lead therapeutic candidate for the treatment
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.